Greatbatch FY 2016 First Quarter Earnings Call. April 28, 2016

Transcription

1 Greatbatch FY 2016 First Quarter Earnings Call April 28,

2 Forward-Looking Statement Some of the statements made in the presentation whether written or oral may be forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of Securities Exchange Act of 1934, as amended, and involve a number of risks and uncertainties. These statements can be identified by terminology such as may, will, should, could, expects, intends, plans, anticipates, believes, estimates, predicts, potential or continue or variations or the negative of these terms or other comparable terminology. These statements are based on the company s current expectations. The company s actual results could differ materially from those stated or implied in such forward-looking statements. The company assumes no obligations to update forward-looking information, including information in this presentation, to reflect changed assumptions, the occurrence of unanticipated events or changes in future operating results, financial conditions or prospects. 2

3 Q1 Earnings Call Presenters Thomas J. Hook President & CEO Michael Dinkins Executive Vice President & Chief Financial Officer 3

4 Agenda Michael Dinkins Financial Review Guidance update Thomas J. Hook Summary Strategic Priorities 1. Drive Organic Growth 2. Integration of acquired companies to expand product offering 3. Growth through innovation of complete medical systems Question & Answer 4

5 Key Financial Metrics Comparable Basis Three Months Ended April 1, April 3, % (Dollars in thousands, except per share data) 2016 (1) 2015 (2) Change Sales $ 331,058 $ 357,867 (7 )% Organic Constant Currency Sales Growth (7 )% GAAP Diluted EPS $ (0.30) $ 0.15 N/A Adjusted Diluted EPS (3) $ 0.42 $ 0.71 (41 )% EBITDA $ 42,191 $ 57,377 (26 )% Adjusted EBITDA (3) $ 65,370 $ 72,045 (9 )% Adjusted EBITDA as a % Sales 19.7 % 20.1 % Adjusted EPS (4) Q Pro forma $ 0.71 Notes Price (0.17) Price concessions to secure customer commitments for LTAs Sales Volume (0.13) Growth in Neuromodulation customers offset by continued decline in Energy market, customer inventory reduction initiatives and product end of life (EOL) Sales Mix/Productivity 0.08 Impact of productivity initiatives and initial phases on synergy plan SG&A 0.12 Reduction driven by execution of synergy plan RD&E (0.07) Customer Reimbursement timing and higher investments in selective projects Interest & Other Gain Losses 0.01 Tax Impact (0.13) Q Comparable Basis $ 0.42 Increase in effective tax rate due to unfavorable mix of GAAP earnings and adjustments in Q1; Actual cash taxes are on target for approx. $10M for total year (1) Comparable basis amounts for 2016 exclude the results of Nuvectra prior to its spin-off. (2) Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical. See the historical pro forma information presentation, which was filed with the SEC on Form 8-k on February 29, 2016, for a reconciliation to As Reported amounts. (3) Refer to Tables A and B at the end of this release for a reconciliation of adjusted amounts to GAAP. (4) The per share data has been rounded to $0.01 and therefore may not sum to the total. 5

6 Product Category Revenues Product Line Advanced Surgical, Orthopedics, and Portable Medical April 1, 2016 (1) Three Months Ended Comparable Basis April 3, 2015 (2) % Change $ 91,329 $ 105,773 (14 )% Cardio and Vascular 133, ,084 (3 )% Cardiac/Neuromodulation 95,895 98,866 (3 )% Electrochem 11,672 17,710 (34 )% Elimination of interproduct line sales (1,488 ) (2,566 ) (42 )% Total Sales $ 331,058 $ 357,867 (7 )% Organic Constant Currency Sales Increase (Decrease) (7)% (1) Comparable basis amounts for 2016 exclude $1.2 million of Nuvectra revenue recognized prior to its spin-off. (2) Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical. See the historical pro forma information presentation, which was filed with the SEC on Form 8-k on February 29, 2016, for a reconciliation to As Reported amounts. 6

7 Advanced Surgical, Orthopedics, and Portable Medical (Sales in $ millions) Q1 R4Q Prior Qtr Sales $91 $404 $105 % total Company 27% 28% 29% Growth (Comparable Basis) -14% -7% -13% Implant Negative impact due to safety stock build-up last year supporting manufacturing transfer Reamer Timing of Orthopaedic customer product launches and inventory reduction initiatives Delivery System Price concessions to secure long term volume commitments Laparoscopic Devices Arthroscopy Products 7

8 Cardio and Vascular (Sales in $ millions) Q1 R4Q Prior Qtr Sales $134 $558 $133 Amounts in millions % total Company 40% 39% 37% Growth (Comparable Basis) -3% -3% 1% Amounts in millions Steerable Sheath Price concessions to secure long term volume commitments Customers working off EOL product inventory making for tough prior year comparable Introducer Focus on high growth sectors Complex, steerable catheter shafts for Electrophysiology market Stents Catheter shafts for peripheral and neuro vascular markets Catheters & Sheaths Guidewires, Stylets & Accessories 8

9 Cardiac/Neuromodulation (Sales in $ millions) Q1 R4Q Prior Qtr Sales $96 $411 $111 % total Company 29% 29% 31% Growth (Comparable Basis) -3% 5% -12% Battery Continued YoY growth in Neuromodulation Feedthrough Customers tightened inventory, timing of product introductions and end of life (EOL) products Enclosure Price concessions to secure long term volume commitments Coated Electrode 9

10 Electrochem (Sales in $ thousands) Q1 R4Q Prior Qtr Sales Amounts in millions $12 $53 $13 % total Company 4% 4% 4% Growth (Comparable Basis) -34% -34% -12% Continued weakness in the global Energy market Battery Cells Battery Packs Battery Chargers 10

11 Balance Sheet Metrics ($ in millions except for EPS) (in $ millions except ratios) Q * Working Capital $318 $361 Working Capital Turnover** Account Receivables $184 $207 Days Sales Outstanding Net Inventory $267 $252 (in $ millions except ratios) Q * Total Debt $1,763 $1,714 Net Leverage Ratio (<6.5)*** Interest Coverage Ratio (>3.0)*** Adjusted RoE** 16.6% 15.0% Days Inventory Outstanding Operating Cash Flow for the quarter was $30M. Increase in debt driven by $76M cash payment for Nuvectra Spin Off. * 2015 Ratios calculated based on pro forma financials for combined company ** Q Ratios estimated based on last 4 quarters for combined company *** Net Leverage Ratio and Interest Coverage ratios are calculated in line with debt covenants 11

12 Guidance The company reconfirms its revenue, Adjusted EBITDA and Adjusted EPS guidance. The revenue guidance is $1.425 billion to $1.475 billion The Adjusted EBITDA guidance is $320 million to $335 million. For the full year 2016, we expect adjusted net income per diluted share to be in the range of $3.00 to $3.35 on 31.5 million fully diluted shares outstanding. For the second quarter of 2016 the Company expects revenue to be in the range of $355 million to $360 million. 12

13 Guidance Selected Financial Guidance Items Affecting Cash Flow: Maintenance Capital Expenditures to be in the range of $50 million - $60 million per year. Depreciation & Amortization is expected to be $100 million - $105 million for Stock compensation expense is expected to be approximately $14 million for Working Capital is expected to be consistent with the prior year. The 2016 adjusted effective tax rate is expected to be approximately 30%; cash taxes are expected to be approximately $10 million for the full year 2016 Other Operating expense is expected to be $55 million - $65 million for the full year 2016 Cash payment for Nuvectra Spin-off was $76 million. The two companies are independent and Greatbatch does not have any ownership in Nuvectra. 13

14 Agenda Michael Dinkins Financial Review Guidance update Thomas J. Hook Summary Strategic Priorities 1. Integration of acquired companies 2. Drive Organic Growth 3. Growth through innovation of complete medical systems Question & Answer 14

15 Executive Summary Q1 Financial Results in line with expectations Difficult comparables to last year CRM, Energy & FX headwinds continue to negatively affect results Neuromodulation growth largely offsetting decline in CRM 2016 Guidance remains unchanged 15

16 Key Strategic Priorities Drive Core product organic growth. Integration of acquired companies. Growth through complete medical device systems in partnership with customers. 16

17 Core Product Organic Growth Strengthen Customer Partnerships Changed from functional to align with customer markets INTEGER will use a single (sales) point of contact for our top strategic customers responsible for strategic relationship management Global Accounts will coordinate all activities across INTEGER s product categories The Technical Solutions team will focus their growth strategy from discrete engineered components through co-developed devices The Product Solutions team will focus on co-developed devices, INTEGER branded solutions and complete medical device systems in partnership with our customers Smaller and single site customers shall be managed through the site customer service/operations resources 17

18 Integration Update Tracking Extremely Well Three organizational phases of integration completed On track to achieve at least $25M of savings in 2016 Line of sight to achieve annual savings of $50M in 2017 and at least $60M in 2018 Years 2-3 largely driven by supply chain and manufacturing optimization 18

19 Growth through Complete Medical Device Systems VALUE The Integer strategy is to significantly increase our value to our customers by increasing the amount of business we have on the right side of the product continuum. SOLUTION COMPLEXITY Engineered Medical Components Engineered Medical Sub Assemblies Differentiated Medical Components & Subassemblies Transfer Devices Co- Developed Devices Integer Designed Devices Fully Branded Solutions Medical Device Systems Technical Solutions (Traditional CMO) Product Solutions (More IP Focused) Global Accounts 19

20 Current Product Continuum Revenue Mix Legacy GB % of Sales Product Solutions, 20.4% Integer % of Sales Technical Solutions, 79.6% Product Solutions, 18.9% Legacy LRM % of Sales Product Solutions, 17.6% Technical Solutions, 81.1% Technical Solutions, 82.4% 20

21 Technology Solutions LRM provides Greatbatch provides INTEGER will provide Electrode Machining Electrode Coating Value added lead assembly Cardiac Lead Components Cardiac Leads & MRI IP Vertically integrated lead solutions Neuro connectors SCS Leads and Adaptors Vertically integrated lead solutions IPG Components IPG Systems Comprehensive Long Term Partnerships 21

22 Product Solutions LRM provides Greatbatch provides INTEGER will provide Sensor Enabled Guidewires Catheter Shafts Peripheral Navigation Solutions Microcatheter Solutions Hub and Valve molding Neurovascular and Drug Delivery Systems Laparoscopic Tools Rechargeable Batteries &Wireless Energy Transfer Portfolio of Tools with Wireless Rechargability Arthroscopic Tools Wireless Power Portfolio of Wireless Surgical Products 22

23 Questions & Answers 23

24 Appendix 24

25 2016 Annual and Q1 Effective Tax Rate Analysis 2016 Annual Effective Tax Rate (AETR): Adjusted AETR is currently forecasted at ~30% Our ETR is generated from the mix of income and tax rates in the various jurisdictions in which we do business: US (35%) ; Mexico (~30%); Ireland (12.5%) ; Germany (~27.5%); France ( ~40%) ; Switzerland (~6%); Uruguay (~25%) Net Operating Losses of ~$393M and $25M exist in the US and Switzerland, respectively. Based on forecasted sources of income; we expect to utilize the NOL s within 10 to 13 years. Cash tax savings are forecasted to be ~$137M No ETR benefit will result from NOL utilization as VA will be released through purchase accounting and will decrease Goodwill Cash taxes (jurisdictions other than US and Switzerland) are estimated at ~$10M Q1 ETR: Adjusted Q1 ETR of ~ 42% on $22.5M of pre-tax income Our adjusted effective tax rate for the first quarter of 2016 was approximately 42% as a result of the Company tax affecting its adjustments at the statutory rate, consistent with its adjusted diluted EPS methodology, but with earnings tax affected at the lower expected full-year effective tax rate for GAAP purposes as required. The impact from these differences is expected to reverse over the remaining three quarters and our full year adjusted effective tax rate is expected to be 30%. The first quarter 2016 GAAP effective tax rate includes a $1.3 million discrete charge related to non-deductible spinrelated expenses, which is added back for adjusted diluted EPS purposes. ASC 740, Accounting for income taxes requires the impact of unusual or infrequently occurring items (e.g., non-deductible transaction costs associated with tax-free Spin) to be excluded from the calculation of the AETR and instead, to be recorded on a discrete basis in the quarter in which they occurred. 25

26 GAAP Reconciliation Net Income and Diluted EPS Reconciliation April 1, 2016 Per Net Diluted Income Share Three Months Ended April 3, 2015 Per Net Diluted Income Share (in thousands except per share amounts) Net income (loss) as reported $ (12,660) $ (0.41) $ 8,008 $ 0.31 Adjustments: Amortization of intangibles (a)(c) 6, , IP related litigation (SG&A) (b)(c) 1, Consolidation and optimization expenses (OOE) (c)(d) 5, , Acquisition and integration expenses (OOE) (c)(e) 6, Asset dispositions, severance and other (OOE) (c)(f) 4, Gain on cost and equity method investments, net (other income, net) (c)(g) (846) (0.03) (324) (0.01) R&D Tax Credit (h) Adjusted net income and diluted EPS (i) $ 10,476 $ 0.34 $ 16,923 $ 0.65 Adjusted diluted weighted average shares 31,253 26,219 a) As a result of our acquisition of Lake Region Medical in the fourth quarter of 2015 and in order to present our financial results in a form more comparable to other medical device companies and less acquisitive companies, during the third quarter of 2015 we began excluding intangible asset amortization for purposes of calculating adjusted net income and adjusted diluted EPS. Prior period adjusted amounts have been recalculated to exclude intangible amortization. b) In 2013, we filed suit against AVX Corporation alleging they were infringing on our intellectual property. Given the complexity and significant costs incurred pursuing this litigation, during the second quarter of 2015, we began excluding these litigation expenses from adjusted amounts. This matter proceeded to trial during the first quarter of 2016 and a federal jury awarded Greatbatch $37.5 million in damages. Prior period adjusted amounts have been recalculated to exclude these costs. c) Net of tax amounts computed using a 35% U.S., Mexico, Germany and France statutory tax rate, a 0% Swiss tax rate, a 25% Uruguay statutory tax rate, and a 12.5% Ireland statutory tax rate. Expenses that are not deductible for tax purposes (i.e. permanent tax differences) are added back at 100%. d) During 2016 and 2015, we incurred costs primarily related to the transfer of our Beaverton, OR portable medical and Plymouth, MN vascular manufacturing operations to Tijuana, Mexico. Additionally, with the acquisition of Lake Region Medical, 2016 costs also include expenses incurred in connection with the closure of Lake Region Medical s Arvada, Colorado site and the consolidation of its two Galway, Ireland sites initiated by Lake Region Medical in e) During 2016, we incurred transaction and integration costs related to the acquisition of Lake Region Medical in October During 2015, we incurred costs related to the integration of CCC Medical Devices which was acquired in August f) Costs primarily include legal and professional fees incurred in connection with the proposed spin-off of Nuvectra, which was completed in March g) Pre-tax amount is a gain of $1.3 million and $0.5 million for the 2016 and 2015 periods, respectively. h) The 2015 Federal R&D tax credit was enacted during the fourth quarter of 2015 and has been permanently reinstated. Amounts assume that the tax credit was effective at the beginning of the year for i) The per share data in this table has been rounded to the nearest $0.01 and therefore may not sum to the total. j) First quarter 2016 adjusted diluted weighted average shares includes 535,000 shares related to outstanding equity awards that were not dilutive for GAAP diluted EPS purposes. 26

27 GAAP Reconciliation Adjusted EBITDA reconciliation Three Months Ended April 1, April 3, (dollars in thousands) Net income (loss) as reported $ (12,660) $ 8,008 Interest expense 27,617 1,120 Provision (benefit) for income taxes (102) 1,812 Depreciation 12,949 5,791 Amortization 9,464 3,387 EBITDA 37,268 20,118 IP related litigation 1, Stock-based compensation 2,029 2,253 Consolidation and optimization expenses 6,649 7,160 Acquisition and integration expenses 9, Asset dispositions, severance and other 4, Noncash (gain) loss on cost and equity method investments (639) (498) Adjusted EBITDA $ 61,705 $ 30,428 Adjusted EBITDA as a % of sales 18.6% 18.9 % * - During the third quarter of 2015, we changed our calculation and presentation of Adjusted EBITDA in order to present our financial results in a form more consistent with other medical device companies, as well as our debt covenant calculations. The primary difference between the current and former calculation is that stock-based compensation is now added back to GAAP net income (loss) to derive Adjusted EBITDA. Prior period adjusted amounts have been recalculated to be presented on a comparable basis. 27

28 Other Operating Expenses 2016 (in $ millions) Q1 15 Q2 15 Q3 15 Q Q Investments and Capacity and Capabilities $6.5 $6.3 $5.1 $5.2 $23.0 $4.2 Portable Medical and Vascular product line transfers Orthopaedic Optimization $0.5 $0.5 $0.4 $1.4 $0.1 Legacy Lake Region Consolidation and Optimization $2.0 $2.0 $2.4 Acquisition and Integration Costs $0.1 $0.1 $5.2 $28.1 $33.5 $10.0 Lake Region Medical and CCC Medical Devices Asset Dispositions, Severance and Other $0.8 $0.9 $3.2 $1.7 $6.6 $4.5 Nuvectra spin off Total OOE $7.9 $7.8 $13.8 $37.0 $66.5 $

29 Contact Information Tony Borowicz Vice President Business Development & Investor Relations Greatbatch Work: Mobile: